Abstract
Hematopoietic stem cell transplantations (HSCT) have increased over the past 30 years with significant improvement in success rate, but the development of secondary malignancies has been recognized as a very serious late complication post-HSCT. Oral leukoplakia (OL), considered a lesion with malignant potential, has been studied in order to find a biomarker that monitors its progression t…